ArticleFrontiers in oncology2025
Transcriptomic analysis reveals TME-mediated macrophage IFIT1 upregulation and CX3CR1 suppression drive osteosarcoma progression.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Osteosarcoma (OS) is one of the most common bone tumors with an unsatisfactory prognosis for patients. Due to the stagnation in conventional treatments, researchers are exploring therapeutic targets from the tumor microenvironment (TME) and tumor-associated macrophages (TAM). Our study investigates how OS TME influences macrophage gene expression, potentially informing OS treatment strategies. Methods: RNA sequencing was performed on bone marrow-derived macrophages (BMMs) cultured with or without K7M2 conditional medium (CM) for 48 h to analyze gene expression changes. Single-cell sequencing and PCR were used to examine the expression levels of IFIT1 and CX3CR1. Their functions were verified through flow cytometry, cloning, wound healing, and transwell assays using IFIT1 protein and CX3CR1 inhibitors. Results: We observed changes in the morphology and transcriptome of BMMs exposed to K7M2 CM. Differentially expressed genes (DEGs) exhibited complex interactions and were enriched in multiple functions and pathways. The upregulation of IFIT1 and the downregulation of CX3CR1 were the most representative. Inhibiting CX3CR1 can promote TAM polarization, thereby accelerating the progression of osteosarcoma. Additionally, increasing IFIT1 also promotes osteosarcoma. Conclusions: Stimulation of the OS TME can change the gene expression of macrophages. Our findings offer a cellular and molecular reference for future investigations of therapeutic targets of OS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.